NEW YORK (Reuters Health)—The oral Janus kinase inhibitor tofacitinib (Xeljanz, Pfizer) does not increase the risk of malignancies, according to pooled data from more than 5000 rheumatoid arthritis (RA) patients. In an April 22 online paper in Annals of the Rheumatic Diseases, Dr. Lisy Wang of Pfizer, Groton, Connecticut, and colleagues noted that in RA…
Search results for: Tofacitinib
Tofacitinib Effective for Treating Moderate-to-Severe Chronic Plaque Psoriasis
NEW YORK (Reuters Health)—Tofacitinib is better than placebo (and noninferior to etanercept) for treating patients with moderate-to-severe chronic plaque psoriasis, according to Pfizer’s OPT Compare trial. In an earlier 12-week, phase 2b, dose-ranging trial, the oral JAK inhibitor tofacitinib proved to be more effective than placebo for treating patients with moderate-to-severe plaque psoriasis. Based on…
Tofacitinib and Other Kinase Inhibitors Offer New Approach to Treating Rheumatoid Arthritis
Small molecule kinase inhibitors, such as JAK inhibitors, provide a novel route for rheumatic disease treatment—and may promote our understanding of the immune system’s complexities
Cardiovascular Risks Similar for JAK Inhibitors & bDMARDs
Using data from registries across Europe and Canada, Aymon et al. compared the incidence of major adverse cardiac events (MACE) in patients with RA treated with JAK inhibitors, TNF inhibitors or biologic DMARDs with other modes of action over two years. The researchers did not find an increased risk of MACE with JAK inhibitors over that time frame.
Sjögren’s Disease: More Than Just a Syndrome
A EULAR 2025 review of Sjögren’s disease covered new pathogenic insights & promising phase 2 data for BTK inhibitors & CD40 pathway drugs.
Key Research in Vasculitis Encapsulated
Summaries of selected research abstracts on the assessment & management of systemic vasculitis from ACR Convergence 2024.
JAK Inhibitors 101
Experts provided an in-depth review of Janus kinase (JAK) inhibitors, discussing the latest research on their use in the treatment of specific rheumatic conditions, the risks associated with them and more.
Trends in the Use of DMARDs for Patients with JIA
Yalamanchili et al. describe how trends in disease-modifying anti-rheumatic drug (DMARD) use have evolved for insured, U.S. patients with juvenile idiopathic arthritis. Overall, the study found that from 2000 to 2022 in this patient population the use of biologic and targeted synthetic DMARDs rose, while the use of conventional synthetic DMARDs declined.
Cancer & RA Drugs: Are Some Drugs Riskier than Others?
Sendaydiego et al. asked: Do some DMARDs pose a greater cancer risk than others for patients with RA? Here are insights from the study and its clinical implications.
Sleep Disorders & Rheumatic Disease
ACR Convergence 2024—With poor sleep a major complaint among patients with rheumatologic diseases, physicians should hone their understanding of how the body regulates sleep and how this system can be disrupted, and tailor their management plans to help patients with these issues, panelists said in a session at ACR Convergence. For some patients, their struggles…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 20
- Next Page »